Organon Pharma Indonesia Tbk (SCPI) Stock 2027: Financial Analysis, Go-Private Risk, and What Investors Should Know
Published: October 30, 2025
Last Updated: October 7, 2026
Financial data and analysis reviewed as of October 7, 2026.
 |
| Organon Pharma Indonesia Tbk (SCPI) |
Worldreview1989 - For investors researching Organon Pharma Indonesia Tbk (SCPI), the most important question for 2027 is not simply whether pharmaceutical earnings will grow.
The bigger question is whether SCPI will still be a publicly traded stock in 2027.
As of October 2026, SCPI is in the middle of a proposed go-private and delisting process. The company's controlling shareholder, Organon LLC, has proposed purchasing shares held by public investors through a voluntary tender offer at Rp100,000 per share. The company has also been a highly unusual Indonesian listed stock because its trading has been suspended for many years.
That changes the investment thesis completely.
For an American investor accustomed to evaluating stocks through liquidity, price discovery, free float, governance, earnings growth, and exit opportunities, SCPI is less comparable to a conventional pharmaceutical stock and more comparable to a corporate-action situation.
Check : Indonesia Stock Exchange Listed Companies Directory
SCPI at a Glance
| Item | SCPI |
|---|---|
| Company | PT Organon Pharma Indonesia Tbk |
| Ticker | SCPI |
| Industry | Pharmaceuticals |
| Shares outstanding | 3.6 million |
| 2025 revenue | Rp4.122 trillion |
| 2025 net profit | Rp290.7 billion |
| 2025 total assets | Rp2.276 trillion |
| 2025 total equity | Rp1.331 trillion |
| 1Q 2026 revenue | Rp863.8 billion |
| 1Q 2026 net profit | Rp86.2 billion |
| Controlling shareholder | Organon LLC |
| Controlling ownership | Approximately 98.8% |
| Proposed tender price | Rp100,000/share |
| Proposed transaction | Go-private and delisting |
The company's 2025 Integrated Annual Report reports net revenue of approximately Rp4.122 trillion, total assets of Rp2.276 trillion, and net profit of Rp290.7 billion.
What American Readers Would Notice First
A U.S. investor looking at SCPI would probably notice something unusual immediately:
SCPI does not behave like a normal publicly traded pharmaceutical stock.
The company has only 3.6 million shares outstanding, while Organon LLC controls approximately 98.8% of the shares. The public float is therefore extremely small.
KSEI's securities database still identifies SCPI as an IDX-listed pharmaceutical security and reports 3.6 million shares outstanding. As of October 7, 2026, approximately 98.79% of the shares were classified as foreign-owned.
The company's 2025 annual report also confirms its historical listing on the Indonesia Stock Exchange under ticker SCPI, dating back to June 8, 1990.
For a U.S. investor, this creates three immediate concerns:
Liquidity risk
Price-discovery risk
Exit risk
These risks are arguably more important than conventional valuation ratios.
2025 Financial Performance: A Stronger Year
SCPI's 2025 financial performance was significantly stronger than 2024.
According to the company's 2025 Integrated Annual Report:
Net revenue increased to approximately Rp4.122 trillion
Net profit reached approximately Rp290.7 billion
Total assets increased to approximately Rp2.276 trillion
The company reported net profit growth of approximately 55.78% compared with 2024.
That is an important positive signal.
The business was not approaching the proposed delisting because of an obvious collapse in profitability.
Instead, the financial data show a profitable pharmaceutical operation operating under a corporate structure dominated by its multinational parent.
1Q 2026: Profitability Remained Positive
The first quarter of 2026 provides another important data point.
SCPI reported:
Revenue: approximately Rp863.8 billion
Gross profit: approximately Rp115.0 billion
EBITDA: approximately Rp110.3 billion
Net profit: approximately Rp86.2 billion
Net profit increased from approximately Rp81.3 billion in 1Q 2025 to Rp86.2 billion in 1Q 2026.
That represents approximately 5.9% year-over-year net-profit growth.
The first-quarter figures therefore suggest that SCPI remained profitable even while its corporate structure was moving toward a potential private-company status.
Financial Ratio Analysis
 |
| Organon Pharma Indonesia Tbk (SCPI) |
Using the reported 2025 numbers, several characteristics stand out.
Profitability
2025 net margin:
Rp290.7 billion / Rp4.122 trillion ≈ 7.1%
That is a respectable level of profitability for a pharmaceutical distribution/manufacturing operation.
The 2025 EBITDA margin was approximately 9.8%, based on EBITDA of around Rp405.8 billion.
Return on Equity
Using reported 2025 net income and equity:
ROE ≈ 21.8%
This is one of the strongest features of the financial profile.
An ROE above 20% can indicate efficient use of shareholder capital, although investors should be careful because SCPI's unusually concentrated ownership and very small public float make conventional public-market comparisons less meaningful.
Debt
2025 figures indicate:
Short-term debt: approximately Rp914.2 billion
Long-term debt: approximately Rp31.1 billion
Total equity: approximately Rp1.331 trillion
This means the company carries meaningful short-term financial obligations.
However, cash was approximately Rp284.9 billion, while EBITDA was approximately Rp405.8 billion.
The key issue for 2027 is therefore not simply whether SCPI has debt.
It is whether the business can continue generating sufficient operating cash flow while maintaining the pharmaceutical business after the transition to private ownership.
The Most Important 2027 Catalyst: Go Private
This is where SCPI becomes fundamentally different from most Indonesian stocks.
In May 2026, SCPI announced plans to become a private company and delist from the Indonesia Stock Exchange.
Organon LLC proposed purchasing the remaining public shares through a voluntary tender offer at:
Rp100,000 per share
The proposed purchase covered as many as 43,664 public shares, representing approximately 1.213% of the company's issued shares. The maximum transaction value was approximately Rp4.37 billion.
The proposed tender price is particularly interesting because SCPI's last traded price before its long suspension was approximately Rp29,000.
That makes Rp100,000 approximately:
244.8% above Rp29,000
or roughly 3.45 times the last traded price.
However, this should not automatically be interpreted as evidence that SCPI is worth 3.45 times its historical market price.
The more important point is that the tender offer is part of a corporate restructuring and liquidity exit mechanism, rather than ordinary stock-market price discovery.
Why SCPI Is Going Private
The company's rationale is especially important for investors.
SCPI's shares have been suspended since 2013, meaning the stock has not provided normal continuous market liquidity.
Management has also cited the low level of public shareholder participation and the company's ability to finance its operations without relying on public-market funding.
The 2026 corporate-action documents explicitly proposed:
delisting from the Indonesia Stock Exchange;
changing the company's status from public to private;
authorizing management to execute the necessary steps for the transaction.
This is a fundamentally different situation from a company delisting because of financial distress.
The financial results actually show a profitable company.
The strategic issue is public-market relevance.
A Critical Development: The Process Has Not Been Straightforward
Investors should not assume that the go-private transaction is automatically completed.
The initial extraordinary shareholders' meeting encountered a quorum problem in July 2026, meaning the proposed transaction did not receive a decision at that meeting.
Later corporate developments continued to show SCPI moving through its corporate restructuring process.
Therefore, the correct analytical approach is:
Go-private is the dominant scenario, but completion should be treated as a transaction risk until all regulatory, shareholder, tender-offer, and delisting requirements have been completed.
That distinction is particularly important for investors considering SCPI around the end of 2026.
2027 Scenario Analysis
Rather than giving a conventional price target, SCPI should be evaluated using three scenarios.
Scenario 1 — Go Private and Delisting Completed
Probability: High, based on the announced corporate plan, but not guaranteed.
Under this scenario, SCPI would no longer function as a normal publicly traded IDX stock during 2027.
The public investor's investment decision would primarily revolve around the tender offer and settlement process.
The proposed Rp100,000 tender price becomes the most relevant reference point for eligible public shareholders.
Investor implication
The upside is not primarily based on earnings growth.
It is based on successfully realizing the corporate-action value.
Scenario 2 — Go-Private Process Delayed
This is a more complicated scenario.
If regulatory, shareholder, or procedural requirements delay the transaction, SCPI could remain technically listed while continuing to face extremely poor liquidity.
In that situation, traditional valuation metrics become less useful.
A company can have:
strong earnings,
positive ROE,
valuable assets,
and still be a very difficult stock to own if shareholders cannot easily buy or sell it.
Investor implication
The major risk becomes liquidity rather than operating performance.
Scenario 3 — Go Private Fails
This is the least attractive scenario from a conventional public-market perspective.
SCPI could remain a listed company while continuing to have:
concentrated ownership,
very small public float,
limited trading activity,
historical suspension issues.
The underlying pharmaceutical business could remain profitable, but the equity could still be unattractive to investors who require regular price discovery.
Unique Analytical Insight: SCPI Is More About Corporate Structure Than Earnings
 |
| Organon Pharma Indonesia Tbk (SCPI) |
This is the most important conclusion of this analysis.
Most pharmaceutical stock analyses begin with:
Revenue → EBITDA → EPS → valuation multiple → target price
For SCPI, that framework is incomplete.
A better framework is:
Business value → ownership structure → liquidity → corporate action → investor exit
That is because the controlling shareholder owns almost the entire company.
The public market therefore has limited influence over corporate strategy.
This also explains why SCPI can show a strong ROE while simultaneously being a poor conventional public-market investment.
A profitable company is not necessarily a liquid stock.
That distinction is often overlooked by retail investors.
What Does Organon's Global Business Tell Us?
The Indonesian subsidiary should also be understood in the context of its multinational parent, Organon & Co.
According to Organon's 2025 SEC-filed annual report, Organon generated approximately $6.216 billion in global revenue in 2025, compared with $6.403 billion in 2024.
The company operates globally across Women's Health, Biosimilars, and Established Brands and sells products in more than 140 countries and territories. Approximately 74% of Organon's 2025 revenue was generated outside the United States.
Organon's 2025 results included approximately $1.91 billion of Adjusted EBITDA, representing a 30.7% Adjusted EBITDA margin.
This provides an important strategic context.
SCPI is not an isolated Indonesian pharmaceutical startup.
It is part of a much larger global pharmaceutical organization.
But Investors Should Not Automatically Apply Organon & Co.'s Valuation to SCPI
This is another critical analytical distinction.
An investor might see Organon & Co.'s global pharmaceutical operations and assume SCPI should receive a comparable valuation.
That would be incorrect.
SCPI has its own:
capital structure,
Indonesian operations,
ownership structure,
financial statements,
regulatory environment,
minority shareholder structure.
The Indonesian subsidiary should therefore be analyzed using its own financial data.
The global parent provides strategic context, not a direct valuation multiple.
What American Investors Should Learn From SCPI
For American readers, SCPI illustrates an important emerging-market investment principle:
Liquidity is an asset.
In U.S. markets, investors often take liquidity for granted.
A stock can generally be bought or sold every trading day with continuously updated market prices.
SCPI demonstrates what happens when that assumption disappears.
An investor can own a profitable business but still face difficulties realizing its value.
That means emerging-market analysis should include:
1. Free float
2. Trading suspension history
3. Controlling shareholder ownership
4. Tender-offer mechanisms
5. Delisting rules
6. Minority shareholder protections
7. Exit mechanisms
These can be as important as P/E or P/B ratios.
SCPI 2027 Investment Scorecard
| Factor | Assessment |
|---|---|
| Revenue growth | Positive |
| Profitability | Positive |
| ROE | Strong |
| Balance sheet | Mixed |
| Global parent support | Strong |
| Public float | Very weak |
| Liquidity | Very weak |
| Trading history | High risk |
| Dividend visibility | Weak |
| Corporate-action potential | Very high |
| 2027 public-market visibility | Very uncertain |
| Conventional stock investment appeal | Low |
Is SCPI Stock a Buy for 2027?
For a conventional long-term stock investor, SCPI should not be treated as a normal 2027 buy candidate.
The reason is not primarily poor financial performance.
The bigger issue is the proposed transition from public to private ownership.
If the go-private process is completed, SCPI would cease to be a normal listed equity opportunity.
Therefore, investors should distinguish between:
Operating business quality
and
Public-stock investability.
The operating business appears considerably healthier than the stock-market situation suggests.
But public-market investability is a different question.
Bull Case
The bullish argument is based on the underlying business.
SCPI has demonstrated:
strong 2025 earnings growth;
positive 1Q 2026 earnings growth;
substantial pharmaceutical operations;
multinational-parent support;
strong historical ROE;
meaningful operating profitability.
If the business continues to perform well, the underlying enterprise value could remain attractive to its controlling shareholder.
Bear Case
The bear case is not necessarily bankruptcy.
It is loss of public-market access.
The biggest risks include:
delayed or failed corporate action;
limited liquidity;
inability to exit at a desired price;
uncertainty around final delisting timing;
concentration of ownership;
absence of normal price discovery;
limited relevance of conventional market valuation multiples.
This is why a strong financial statement does not automatically translate into a strong stock investment.
2027 Outlook
My base-case view is that SCPI should be viewed as a corporate-action story rather than a conventional 2027 growth stock.
If the announced go-private and delisting process is completed, there may be no ordinary SCPI stock available to buy on the IDX in 2027.
The company's underlying pharmaceutical business may continue operating and potentially grow, but public shareholders would no longer have the same exposure to that business through an actively traded IDX security.
Therefore:
2027 Business Outlook: Moderately Positive
2027 Public-Equity Outlook: Highly Uncertain
Liquidity Outlook: Very Weak
Corporate-Action Outlook: Highly Significant
Conventional Buy-and-Hold Stock Rating: Not Attractive Until the Corporate Status Is Resolved
Bottom Line
Organon Pharma Indonesia Tbk (SCPI) is an unusual investment case.
The financial numbers do not describe a weak pharmaceutical company. In 2025, SCPI generated approximately Rp4.12 trillion of revenue and Rp290.7 billion of net profit, while 1Q 2026 remained profitable.
The real investment problem is the structure of the equity.
Organon LLC controls approximately 98.8% of SCPI, the public float is extremely small, and the company has pursued a go-private and delisting transaction with a proposed tender price of Rp100,000 per share.
For that reason, investors should not approach SCPI in 2027 simply by asking:
“What will SCPI's P/E ratio be?”
The better question is:
“Will SCPI still be a publicly traded investment opportunity in 2027?”
That is the central issue.
For American readers, SCPI is a particularly useful case study in why liquidity, ownership concentration, corporate governance, and exit mechanisms can matter just as much as earnings growth when investing in emerging markets.
Primary Sources and Investor References
PT Organon Pharma Indonesia Tbk — 2025 Integrated Annual Report
Organon Pharma Indonesia — 2025 Integrated Annual Report
PT Organon Pharma Indonesia Tbk — Corporate Information
Organon Pharma Indonesia Corporate Information
Kustodian Sentral Efek Indonesia — SCPI Securities Information
KSEI — Organon Pharma Indonesia (SCPI) Securities Information
Organon & Co. — 2025 Form 10-K, U.S. SEC
SEC — Organon & Co. 2025 Form 10-K
Organon & Co. — 2025 Financial Results, U.S. SEC Filing
SEC — Organon 2025 Financial Results
SCPI Go-Private / Delisting Corporate Action Documentation
KSEI — SCPI RUPSLB Announcement
About the Author
Investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Alternative Assets
- Business & Startups
- Franchise
- Insurance
- Property and Real Estate
- Stocks
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks.